"There is a whole lot of reshuffling going on companywide," said Melinda Stubbee. "Unfortunately, as part of that process, jobs are going to be lost."
The layoffs have been in the works for weeks, said Stephen Frye, GSK's former head of drug discovery, who joined the UNC-Chapel Hill faculty last year. Frye said he has been talking to several former colleagues who were worried about losing their jobs.
GSK plans to eliminate half of about 500 jobs at its two research and development centers in Philadelphia and Research Triangle Park, Frye said his former colleagues told him. The centers are involved in finding treatments for cardiovascular and metabolic diseases, including diabetes.
Looks like it's not a bad time to enroll in a PharmD Programme.
At the same time, GSK is shifting research and development activities to lower-cost countries, including China, and partnering with smaller biotech companies to come up with new drugs.
More
No comments:
Post a Comment